Platelet refractoriness - practical approaches and ongoing dilemmas in patient management

Simon J. Stanworth; Cristina Navarrete; Lise Estcourt; Judith Marsh

doi:10.1111/bjh.13597

Platelet refractoriness - practical approaches and ongoing dilemmas in patient management

Simon J. Stanworth^*, Cristina Navarrete, Lise Estcourt, Judith Marsh

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

209 Citations (Scopus)

Abstract

Platelet refractoriness can represent a significant clinical problem that complicates the provision of platelet transfusions, is associated with adverse clinical outcomes and increases health care costs. Although it is most frequently due to non-immune platelet consumption, immunological factors are also often involved. Human leucocyte antigen (HLA) alloimmunization is the most important immune cause. Despite the fact that systematic reviews of the clinical studies evaluating different techniques for selecting HLA compatible platelets have not been powered to demonstrate improved clinical outcomes, platelet refractoriness is currently managed by the provision of HLA-matched or cross matched platelets. This review will address a practical approach to the diagnosis and management of platelet refractoriness while highlighting on-going dilemmas and knowledge gaps.

Original language	English
Pages (from-to)	297-305
Number of pages	9
Journal	British Journal of Haematology
Volume	171
Issue number	3
Early online date	20 Jul 2015
DOIs	https://doi.org/10.1111/bjh.13597
Publication status	Published - 1 Nov 2015

Keywords

Alloimmunization
Human leucocyte antigen antibodies
Platelet transfusions

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.13597

Cite this

@article{3803b8336f0745da8aaf2c8830cc8a85,

title = "Platelet refractoriness - practical approaches and ongoing dilemmas in patient management",

abstract = "Platelet refractoriness can represent a significant clinical problem that complicates the provision of platelet transfusions, is associated with adverse clinical outcomes and increases health care costs. Although it is most frequently due to non-immune platelet consumption, immunological factors are also often involved. Human leucocyte antigen (HLA) alloimmunization is the most important immune cause. Despite the fact that systematic reviews of the clinical studies evaluating different techniques for selecting HLA compatible platelets have not been powered to demonstrate improved clinical outcomes, platelet refractoriness is currently managed by the provision of HLA-matched or cross matched platelets. This review will address a practical approach to the diagnosis and management of platelet refractoriness while highlighting on-going dilemmas and knowledge gaps.",

keywords = "Alloimmunization, Human leucocyte antigen antibodies, Platelet transfusions",

author = "Stanworth, {Simon J.} and Cristina Navarrete and Lise Estcourt and Judith Marsh",

year = "2015",

month = nov,

day = "1",

doi = "10.1111/bjh.13597",

language = "English",

volume = "171",

pages = "297--305",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Platelet refractoriness - practical approaches and ongoing dilemmas in patient management

AU - Stanworth, Simon J.

AU - Navarrete, Cristina

AU - Estcourt, Lise

AU - Marsh, Judith

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Platelet refractoriness can represent a significant clinical problem that complicates the provision of platelet transfusions, is associated with adverse clinical outcomes and increases health care costs. Although it is most frequently due to non-immune platelet consumption, immunological factors are also often involved. Human leucocyte antigen (HLA) alloimmunization is the most important immune cause. Despite the fact that systematic reviews of the clinical studies evaluating different techniques for selecting HLA compatible platelets have not been powered to demonstrate improved clinical outcomes, platelet refractoriness is currently managed by the provision of HLA-matched or cross matched platelets. This review will address a practical approach to the diagnosis and management of platelet refractoriness while highlighting on-going dilemmas and knowledge gaps.

AB - Platelet refractoriness can represent a significant clinical problem that complicates the provision of platelet transfusions, is associated with adverse clinical outcomes and increases health care costs. Although it is most frequently due to non-immune platelet consumption, immunological factors are also often involved. Human leucocyte antigen (HLA) alloimmunization is the most important immune cause. Despite the fact that systematic reviews of the clinical studies evaluating different techniques for selecting HLA compatible platelets have not been powered to demonstrate improved clinical outcomes, platelet refractoriness is currently managed by the provision of HLA-matched or cross matched platelets. This review will address a practical approach to the diagnosis and management of platelet refractoriness while highlighting on-going dilemmas and knowledge gaps.

KW - Alloimmunization

KW - Human leucocyte antigen antibodies

KW - Platelet transfusions

UR - http://www.scopus.com/inward/record.url?scp=84944274683&partnerID=8YFLogxK

U2 - 10.1111/bjh.13597

DO - 10.1111/bjh.13597

M3 - Article

C2 - 26194869

AN - SCOPUS:84944274683

SN - 0007-1048

VL - 171

SP - 297

EP - 305

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Platelet refractoriness - practical approaches and ongoing dilemmas in patient management

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this